Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors
10.3988/jcn.2020.16.4.674
- Author:
Hyun Jae KIM
1
;
Seonkyung LEE
;
Yu Jin KOO
;
Eunjin KWON
;
Hyo-Jung KIM
;
Jeong-Yoon CHOI
;
Ji-Soo KIM
Author Information
1. Dizziness Center, Clinical Neuroscience Center, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology
2020;16(4):674-680
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background:and Purpose: Orbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective.
Methods:We reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment.
Results:The three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation.
Conclusions:Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.
